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Carcinoid tumors of the gastrointestinal tract are distinc-tive endocrine neoplasms commonly found in thesmall bowel and appendix; however, they are exceed-ingly uncommon in the esophagus. It was first reported
in 1974 that esophageal carcinoids arise from the argyrophil en-
docrine cells, which are amine precursor uptake and decarboxyl-
ation cells of the mucosa.1 The aggressiveness of atypical carci-
noid of the esophagus often precludes the use of limited surgical
resection and requires adjuvant chemoradiotherapy.2 Here we re-
port our successful palliative management of an advanced esoph-
ageal atypical carcinoid with tracheal invasion using a covered
Ultraflex expandable metallic tracheal stent (Boston Scientific,
Galway, Ireland) and oral thalidomide.
Clinical Summary
A 73-year-old man presented with a 6-month history of progres-
sive dysphagia and 2-kg body weight loss. At the time of presen-
tation, full diet was still tolerable but with a slow pace. No clinical
features of carcinoid syndrome were noted. The esophagoscopic
examination revealed a 1.7-cm polypoid mass at the upper-third
esophagus, 20 cm below the incisor. Chest computed tomography
revealed an esophageal tumor at the upper-third portion with
invasion to the trachea (Figure 1, A). The bronchoscope showed
multiple intraluminal tumors over the upper trachea, causing mild
obstruction. The panendoscopic and bronchoscopic biopsies did
not provide an adequate specimen for pathologic examination.
Further intervention was suggested to establish a definite diagnosis
but was declined by the patient. After 1 year, he returned to our
hospital with severe dyspnea caused by the enlarging tracheal
tumors. A tracheal Ultraflex stent was inserted on an emergency
basis and airway obstruction was relieved immediately. The bron-
choscopic and panendoscopic biopsies were repeated, showing
submucosal aggregation of oncocytic neoplastic cells in glandular
arrangement with occasional colloid-like secretion microscopi-
cally (Figure 2, A). The tumor cells were immunoreactive
to cytokeratin, neuron-
specific enolase, chro-
mogranin (Figure 2,
B), and synaptophysin
but negative for smooth
muscle actin, indicative of a carcinoid. Diagnosis of atypical
carcinoid tumor was reached owing to increased mitotic activity,
nuclear polymorphism, increased cellularity with disorganized ar-
chitecture, and focal tumor necrosis in places. Curative operation
was precluded for advanced disease, and no effective chemother-
apy was available for this rare neoplasm. Radiotherapy was unac-
ceptable to the patient, and oral thalidomide was prescribed as a
palliative therapy. During a 30-month follow-up, the patient is
living well with the disease. Currently, the extent of disease
remains stationary, with the patient reporting only mild dysphagia
(Figure 1, B).
Discussion
Carcinoid tumors have been reported as occurring throughout the
gastrointestinal tract, most commonly in the small bowel, appen-
dix, and rectum, but they are exceedingly uncommon in the esoph-
agus. They usually occur in older men who have dysphagia,
demonstrating no clinical specificity compared with esophageal
adenocarcinoma or squamous cell carcinoma. In all the reported
cases, the patients had dysphagia, and only one had the carcinoid
syndrome.2 Therefore, it is difficult to differentiate esophageal
carcinoid tumors clinically from adenocarcinoma and squamous
cell carcinoma. The final diagnosis depends on the microscopic
and immunohistochemical features. Because atypical carcinoid is
an intermediate malignancy with aggressive ability, it is necessary
to differentiate atypical carcinoid from other tumors. The histo-
logic appearance of an atypical carcinoid is established according
to the criteria proposed by Arrigoni, Woolner, and Bernatz3: (1)
increased mitotic activity in the presence of recognizable carcinoid
pattern; (2) pleomorphism, nuclear irregularity, hyperchromatism,
and abnormal nuclear/cytoplasmic ratio; (3) hypercellularity with
disorganization of the architecture; and (4) areas of tumor necro-
ses. Some authors suggest that the aggressive behavior of atypical
carcinoid of the esophagus precludes the use of limited surgical
resection and requires adjuvant chemoradiotherapy.2 In our case,
the patient had advanced esophageal atypical carcinoid tumor with
tracheal invasion, which required tracheal stenting. Oral thalido-
mide was prescribed because of our previous successful experi-
ences with thalidomide as an adjuvant therapy for patients with
malignant solitary fibrous tumor, margin-involved desmoids, and
unresectable metastatic osteosarcoma.4 Thalidomide is postulated
to have antiangiogenic activity through its ability to interfere with
the vascular endothelial growth factor and basic fibroblast growth
factor pathways. This activity was proved with apparent disease
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stabilization in a recent phase II study of patients with metastatic
neuroendocrine tumors.5 After being followed up for 30 months,
our patient still has a good quality of life except for only mild
dysphagia.
In summary, esophageal atypical carcinoid is a rare disease.
When it is localized, surgical intervention is the treatment of
choice. However, when metastasis or local infiltration is present,
the outlook is poor despite radical resection and adjuvant chemo-
radiotherapy. Our case demonstrates a worthwhile experience of
palliative therapy with tracheal stent insertion and oral thalidomide
for this advanced malignant tumor.
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Figure 1. A, Initial chest computed tomographic scan showed the
esophageal tumor with invasion to the trachea. B, Several months
later, a follow-up scan showed the tumor size was stationary
under thalidomide usage and the tracheal stent was noted in situ.
Figure 2. A, The polypoid nodule of the trachea demonstrated
oncocytic neoplastic glands with occasional colloid-like secre-
tion in the submucosa; B, Strongly chromogranin immunoreactive
tumor cells.
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